|
Name |
2-methyl-actinomycin D
|
Molecular Formula | C62H88N12O16 | |
IUPAC Name* |
1-N,9-N-bis[7,14-dimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-2-(methylamino)-3-oxophenoxazine-1,9-dicarboxamide
|
|
SMILES |
CNc1c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(O)OC2C)c2nc3c(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)NC(C(C)C)C(=O)OC4C)ccc(C)c3oc-2c(C)c1=O
|
|
InChI |
InChI=1S/C62H88N12O16/c1-27(2)41-59(84)73-23-17-19-36(73)57(82)70(14)25-38(75)64-43(29(5)6)61(86)88-33(11)44(55(80)66-41)68-53(78)35-22-21-31(9)51-46(35)65-48-40(47(63-13)50(77)32(10)52(48)90-51)54(79)69-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-71(15)58(83)37-20-18-24-74(37)60(85)42(28(3)4)67-56(45)81/h21-22,27-30,33-34,36-37,41-45,49,62-63,87H,17-20,23-26H2,1-16H3,(H,64,75)(H,66,80)(H,67,81)(H,68,78)(H,69,79)
|
|
InChIKey |
GWQHZZNBEZCYGI-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 1257.45 | ALogp: | 0.6 |
HBD: | 7 | HBA: | 18 |
Rotatable Bonds: | 9 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 357.9 | Aromatic Rings: | 7 |
Heavy Atoms: | 90 | QED Weighted: | 0.116 |
Caco-2 Permeability: | -5.973 | MDCK Permeability: | 0.00000498 |
Pgp-inhibitor: | 0.713 | Pgp-substrate: | 1 |
Human Intestinal Absorption (HIA): | 0.978 | 20% Bioavailability (F20%): | 0.089 |
30% Bioavailability (F30%): | 0.942 |
Blood-Brain-Barrier Penetration (BBB): | 0.041 | Plasma Protein Binding (PPB): | 97.71% |
Volume Distribution (VD): | 0.399 | Fu: | 1.30% |
CYP1A2-inhibitor: | 0 | CYP1A2-substrate: | 0.017 |
CYP2C19-inhibitor: | 0.029 | CYP2C19-substrate: | 0.062 |
CYP2C9-inhibitor: | 0.097 | CYP2C9-substrate: | 0.089 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.075 |
CYP3A4-inhibitor: | 0.581 | CYP3A4-substrate: | 0.916 |
Clearance (CL): | 3.066 | Half-life (T1/2): | 0.291 |
hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.982 |
Drug-inuced Liver Injury (DILI): | 0.95 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.823 | Maximum Recommended Daily Dose: | 0.03 |
Skin Sensitization: | 0.031 | Carcinogencity: | 0.009 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0 |
Respiratory Toxicity: | 0.012 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003375 | 0.781 | D0P8IV | 0.781 | ||||
ENC000998 | 0.737 | D05MNW | 0.332 | ||||
ENC005563 | 0.262 | D07XGH | 0.332 | ||||
ENC000948 | 0.246 | D0J7XL | 0.308 | ||||
ENC002129 | 0.243 | D0O3YF | 0.303 | ||||
ENC002857 | 0.241 | D0L9HX | 0.301 | ||||
ENC002406 | 0.237 | D0E2OU | 0.293 | ||||
ENC003271 | 0.237 | D06TOE | 0.235 | ||||
ENC002483 | 0.237 | D0F9BY | 0.226 | ||||
ENC003706 | 0.235 | D00GNJ | 0.224 |